Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Ayala Pharmaceuticals stock opened at $0.03 on Friday. The stock has a market capitalization of $1.28 million, a PE ratio of 0.00 and a beta of 1.63. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.97. The company has a 50 day moving average of $0.03 and a 200-day moving average of $0.04.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.